A vaccine remains a priority in the global fight against malaria. Here, we report on a single-
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …

Radical control of malaria likely requires a vaccine that targets both the asymptomatic liver
stages and the disease-causing blood stages of the human malaria parasite Plasmodium …

Background Two current leading malaria blood-stage vaccine candidate antigens for
Plasmodium falciparum, the C-terminal region of merozoite surface protein 1 (MSP119) and …

Background The development of an asexual blood stage vaccine against Plasmodium
falciparum malaria based on the major merozoite surface protein-1 (MSP1) antigen is …

MSP2 is an intrinsically disordered protein that is abundant on the merozoite surface and
essential to the parasite Plasmodium falciparum. Naturally-acquired antibody responses to …

Background Overcoming antigenic diversity is a key challenge in the development of
effective Plasmodium falciparum malaria vaccines. Strategies that promote the generation of …

Objectives To assess the safety and immunogenicity of two vaccines, MSP142-
FVO/Alhydrogel and MSP142-3D7/Alhydrogel, targeting blood-stage Plasmodium …

Background Surrogate markers of protective immunity to malaria in humans are needed to
rationalize malaria vaccine discovery and development. In an effort to identify such markers …

Although merozoite surface protein 1 (MSP-1) is a leading candidate vaccine antigen for
blood-stage malaria, its efficacy in clinical trials has been limited in part by antigenic …

The most widespread Plasmodium species, Plasmodium vivax, poses a significant public
health threat. An effective vaccine is needed to reduce global malaria burden. Of the …